Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2015 Aug 8

PMID 26251902

Citations 29

Authors

Sebastian Steven

Thomas Munzel

Andreas Daiber

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease is a leading cause of death and reduced quality of life worldwide. Arterial vessels are a primary target for endothelial dysfunction and atherosclerosis, which is accompanied or even driven by increased oxidative stress. Recent research in this field identified different sources of reactive oxygen and nitrogen species contributing to the pathogenesis of endothelial dysfunction. According to lessons from the past, improvement of endothelial function and prevention of cardiovascular disease by systemic, unspecific, oral antioxidant therapy are obviously too simplistic an approach. Source- and cell organelle-specific antioxidants as well as activators of intrinsic antioxidant defense systems might be more promising. Since basic research demonstrated the contribution of different inflammatory cells to vascular oxidative stress and clinical trials identified chronic inflammatory disorders as risk factors for cardiovascular events, atherosclerosis and cardiovascular disease are closely associated with inflammation. Therefore, modulation of the inflammatory response is a new and promising approach in the therapy of cardiovascular disease. Classical anti-inflammatory therapeutic compounds, but also established drugs with pleiotropic immunomodulatory abilities, demonstrated protective effects in various models of cardiovascular disease. However, results from ongoing clinical trials are needed to further evaluate the value of immunomodulation for the treatment of cardiovascular disease.

Citing Articles

Vascular endothelial cell injury: causes, molecular mechanisms, and treatments.

Xia T, Yu J, Du M, Chen X, Wang C, Li R MedComm (2020). 2025; 6(2):e70057.

PMID: 39931738 PMC: 11809559. DOI: 10.1002/mco2.70057.

Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies.

Das D, Shruthi N, Banerjee A, Jothimani G, Duttaroy A, Pathak S Front Nutr. 2023; 10:1221438.

PMID: 37614749 PMC: 10442661. DOI: 10.3389/fnut.2023.1221438.

Role of CD40(L)-TRAF signaling in inflammation and resolution-a double-edged sword.

Strohm L, Ubbens H, Munzel T, Daiber A, Daub S Front Pharmacol. 2022; 13:995061.

PMID: 36267276 PMC: 9577411. DOI: 10.3389/fphar.2022.995061.

Repositioning Linagliptin for the Mitigation of Cadmium-Induced Testicular Dysfunction in Rats: Targeting HMGB1/TLR4/NLRP3 Axis and Autophagy.

Arab H, Elhemiely A, El-Sheikh A, Khabbaz H, Arafa E, Ashour A Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890148 PMC: 9319949. DOI: 10.3390/ph15070852.

Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs.

Thomas C, Wurzer L, Malle E, Ristow M, Madreiter-Sokolowski C Front Aging. 2022; 3:905261.

PMID: 35821802 PMC: 9261327. DOI: 10.3389/fragi.2022.905261.

References

Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H . Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355(12):1210-21. DOI: 10.1056/NEJMoa060186. View

Steinhubl S . Why have antioxidants failed in clinical trials?. Am J Cardiol. 2008; 101(10A):14D-19D. DOI: 10.1016/j.amjcard.2008.02.003. View

Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R . IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol. 2010; 184(8):4531-7. DOI: 10.4049/jimmunol.0903162. View

Oppermann M, Balz V, Adams V, Thao-Vi Dao V, Bas M, Suvorava T . Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo. J Cell Mol Med. 2009; 13(7):1271-8. PMC: 4496141. DOI: 10.1111/j.1582-4934.2008.00627.x. View

Porsti I, Bara A, Busse R, Hecker M . Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 1994; 111(3):652-4. PMC: 1910086. DOI: 10.1111/j.1476-5381.1994.tb14787.x. View

Harris R, Pedersen-White J, Guo D, Stallmann-Jorgensen I, Keeton D, Huang Y . Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens. 2011; 24(5):557-62. PMC: 3812921. DOI: 10.1038/ajh.2011.12. View

Mozos I, Marginean O . Links between Vitamin D Deficiency and Cardiovascular Diseases. Biomed Res Int. 2015; 2015:109275. PMC: 4427096. DOI: 10.1155/2015/109275. View

Hibbert B, Simard T, Ramirez F, Pourdjabbar A, Raizman J, Maze R . The effect of statins on circulating endothelial progenitor cells in humans: a systematic review. J Cardiovasc Pharmacol. 2013; 62(5):491-6. DOI: 10.1097/FJC.0b013e3182a4027f. View

Shuvaev V, Christofidou-Solomidou M, Bhora F, Laude K, Cai H, Dikalov S . Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther. 2009; 331(2):404-11. PMC: 2775262. DOI: 10.1124/jpet.109.156877. View

10.

Oberle S, Abate A, Grosser N, Hemmerle A, Vreman H, Dennery P . Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood). 2003; 228(5):529-34. DOI: 10.1177/15353702-0322805-21. View

11.

Domenighetti G, Suter P, Schaller M, Ritz R, Perret C . Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1998; 12(4):177-82. DOI: 10.1016/s0883-9441(97)90029-0. View

12.

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

13.

Dikalova A, Bikineyeva A, Budzyn K, Nazarewicz R, McCann L, Lewis W . Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 2010; 107(1):106-16. PMC: 2901409. DOI: 10.1161/CIRCRESAHA.109.214601. View

14.

Crispin J, Tsokos G . IL-17 in systemic lupus erythematosus. J Biomed Biotechnol. 2010; 2010:943254. PMC: 2850519. DOI: 10.1155/2010/943254. View

15.

Farghali H, Kutinova Canova N, Lekic N . Resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol Res. 2012; 62(1):1-13. DOI: 10.33549/physiolres.932434. View

16.

Oeseburg H, de Boer R, Buikema H, van der Harst P, van Gilst W, Sillje H . Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010; 30(7):1407-14. DOI: 10.1161/ATVBAHA.110.206425. View

17.

Zhou R, Yazdi A, Menu P, Tschopp J . A role for mitochondria in NLRP3 inflammasome activation. Nature. 2010; 469(7329):221-5. DOI: 10.1038/nature09663. View

18.

Bjelakovic G, Gluud L, Nikolova D, Whitfield K, Wetterslev J, Simonetti R . Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014; (1):CD007470. PMC: 11285307. DOI: 10.1002/14651858.CD007470.pub3. View

19.

Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y . Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014; 232(1):156-64. DOI: 10.1016/j.atherosclerosis.2013.10.025. View

20.

Doyle M, Egan J . Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007; 113(3):546-93. PMC: 1934514. DOI: 10.1016/j.pharmthera.2006.11.007. View